Under the terms of the agreement, Dr Reddy’s will be responsible for the development, manufacturing and marketing of the drug product, which will utilize Scolr’s CDT technology. Scolr Pharma will be responsible for the formulation and assisting with product scale-up activities.
The agreement provides double-digit participation in net profits for Scolr Pharma after recovery of development and commercialization expenses associated with the potential product, according to the US-based company. Other financial terms of the agreement have not been disclosed.